Novacyt S.A. (ALNOV.PA) News
Track canonical SquawkNews coverage tagged to ALNOV.PA, Novacyt S.A.. This hub brings together deduplicated headlines about paris, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Novacyt loss narrows 9% to GBP 5.79 million in six months to June 30, 2026
Loss after tax attributable to owners narrowed 9% to GBP 5.79 million; revenue rose 18% to GBP 11.56 million for the six months ended June 30, 2026.
EARNINGS | Sep 30, 2026, 07:45 AM UTC
M
Novacyt H1 revenue rises 18% to £11.6m after Southern Cross Diagnostics acquisition
France molecular diagnostics firm Novacyt said H1 revenue rose 18% year-on-year to £11.6m. Gross margin fell to 56% from 66%, citing dilution from Southern Cross Diagnostics and lower Primer Design sales; it expects cont
EARNINGS | Sep 30, 2026, 06:26 AM UTC